Dynavax Technologies Corporation Q3 2025 Earnings Recap

DVAX Q3 2025 November 6, 2025

Get alerts when DVAX reports next quarter

Dynavax Technologies delivered robust third quarter results, highlighted by a 13% year-over-year increase in net product revenue for HEPLISAV-B and strategic advancement in its clinical pipeline, including an exclusive license for a novel oral COVID-19 vaccine candidate.

Earnings Per Share Beat

$0.21 vs $0.14 est.

+50.0% surprise

Revenue Beat

94876000 vs 80262670 est.

+18.2% surprise

Market Reaction

1-Day +6.7%

5-Day +9.42%

30-Day +3.98%

See DVAX alongside your other holdings

Add to your portfolio — free

Key Takeaways

HEPLISAV-B generated $90 million in net revenue, achieving a 46% market share in the U.S. adult hepatitis B vaccine market.
The company announced a new $100 million share repurchase program, reinforcing its commitment to shareholder value.
Dynavax entered into a strategic partnership with Vaxart for a Phase IIb COVID-19 oral vaccine candidate, targeting a significant unmet need in COVID-19 prevention.
Continued momentum in clinical pipeline advancement, with key developments in shingles and pandemic flu vaccine candidates underway.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit DVAX on AllInvestView.